Allena Pharmaceuticals, Inc. Stock: price and insider trades · United States

Allena Pharmaceuticals, Inc. was a United States biopharmaceutical company headquartered in Newton, Massachusetts, and associated with a U.S. public-market listing on the Nasdaq/NYSE universe as reflected in SEC filings. For French-, Belgian- and Swiss-based investors, the company belongs in the Health & Pharma bucket, more specifically in specialty biotechnology. Based on SEC disclosures, Allena was formed to discover, develop, and commercialize first-in-class oral enzyme therapeutics targeting rare and severe metabolic and kidney disorders. The company’s core scientific identity was therefore highly focused rather than diversified, with a business model typical of clinical-stage biotech: build a pipeline, generate clinical data, seek regulatory alignment, and only later attempt commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1624658/000156459020010991/alna-10k_20191231.htm?utm_source=openai))

Allena’s best-known asset was reloxaliase, an oral enzyme therapeutic intended to reduce intestinal oxalate absorption and thereby address hyperoxaluria, a metabolic disorder linked to kidney stones, chronic kidney disease, and other serious renal complications. This positioned the company in a very specialized niche with a clearly defined unmet medical need. Strategically, the appeal of the asset was its oral administration and its potential to deliver a differentiated mechanism of action in a rare-disease setting. In competitive terms, Allena was not a broad-platform pharmaceutical company; it was a focused development-stage player whose valuation depended heavily on clinical efficacy, safety, and regulatory progress. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1624658/000119312519286673/d831178dex991.htm?utm_source=openai))